Research Progress of m6A Methylation Modification in Hematological Tumors--Review.
10.19746/j.cnki.issn.1009-2137.2022.05.048
- Author:
Feng LI
1
;
Fei-Fei YANG
1
;
Yan-Li XU
2
Author Information
1. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.
2. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.E-mail: xuyanli62@sohu.com.
- Publication Type:Review
- Keywords:
N6-methyladenosine;
hematological tumor;
methylation;
tumor immunity
- MeSH:
Adenosine/metabolism*;
Epigenesis, Genetic;
Hematologic Neoplasms/genetics*;
Humans;
Methylation;
Neoplasms/metabolism*;
RNA, Messenger/metabolism*
- From:
Journal of Experimental Hematology
2022;30(5):1607-1611
- CountryChina
- Language:Chinese
-
Abstract:
N6-methyladenosine (m6A) is one of the most common epigenetic modifications of eukaryotic mRNAs, which is involved in the regulation of gene expressions and biological processes in a variety of cells with dynamic and reversible methylation processes. In recent years, many studies have shown that m6A methylation modification not only acts on the growth, proliferation, and medullary differentiation of acute myeloid leukemia cells, but also participates in the regulation of the proliferation and apoptosis of other hematological tumor cells such as chronic myeloid leukemia and diffuse large B-cell lymphoma, and it can even weaken the efficacy of anti-hematological tumor immunotherapy and induce immune escape leading to tumor resistance. With the successive development of a variety of m6A methylation-related enzyme inhibitors, it will provide new therapeutic ideas for patients with relapsed and refractory hematological tumors. In this paper, we review the research progress on the mechanism of m6A methylation on the occurrence, development, and tumor immunity of various hematological tumors.
